DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > University Hospital > Articles in academic journal >

Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings


File Description SizeFormat
Cancers11_1769.pdf1.81 MBAdobe PDFView/Open

Title: Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings
Authors: Sasaki, Ryu / Fukushima, Masanori / Haraguchi, Masafumi / Miuma, Satoshi / Miyaaki, Hisamitsu / Hidaka, Masaaki / Eguchi, Susumu / Matsuo, Satoshi / Tajima, Kazuaki / Matsuzaki, Toshihisa / Hashimoto, Satsuki / Ooba, Kazuo / Kugiyama, Yuki / Yatsuhashi, Hiroshi / Motoyoshi, Yasuhide / Shigeno, Masaya / Kinoshita, Noboru / Nakao, Kazuhiko
Issue Date: 10-Nov-2019
Publisher: MDPI
Citation: Cancers, 11(11), art.no.1769; 2019
Abstract: Background: Lenvatinib is currently available as the first-line treatment for advanced unresectable hepatocellular carcinoma. We evaluated the relationship between its relative dose intensity (RDI) and response in clinical settings. Methods: From March 2018 to May 2019, 93 patients were administered lenvatinib at the Nagasaki University Hospital and its related facilities. Among these, 81 patients (66 men, 15 women, median age 72.0) who received lenvatinib were analyzed retrospectively. Results: Fourteen patients were Child–Pugh grade B, and 15 had received other systemic therapy. According to Response Evaluation Criteria in Solid Tumors (RECIST), the objective response (OR) rate was 17.3%. The overall survival (OS) was significantly better in the OR group (p = 0.011). There was a significant difference in RDI between the OR and non-OR groups (p < 0.05). The area under the receiver operating characteristics curve for OR prediction by the 4, 8, 12, and 16-week RDI were 0.666, 0.747, 0.731, and 0.704, respectively. In the 8-week RDI ≥67.0% group, OS was significantly better than in the 8-week RDI< 67.0% group (p = 0.003). Conclusions: Because a sufficient RDI is required to achieve an OR, it is strongly recommended that lenvatinib should be administered to patients with good hepatic function and status.
Keywords: hepatocellular carcinoma / lenvatinib / relative dose intensity
URI: http://hdl.handle.net/10069/39551
DOI: 10.3390/cancers11111769
Rights: © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Type: Journal Article
Text Version: publisher
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/39551

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace